Telmisartan + Amlodipine

Generic NameTelmisartan + Amlodipine

Therapeutic ClassARB + Calcium Channel Blocker

Max / 24hTelmisartan 80 mg / Amlodipine 10 mg

Common DoseTelmisartan 40 mg + Amlodipine 5 mg once daily; may increase to 80/10 mg if needed

PregnancyContraindicated in 2nd and 3rd trimester (Telmisartan)

Indications ▼

Essential hypertension in adults inadequately controlled with monotherapy

Hypertension with high cardiovascular risk (stroke, myocardial infarction, diabetes, kidney disease)

Patients with left ventricular hypertrophy

Patients requiring combination therapy to achieve target blood pressure

Secondary prevention in hypertensive patients with renal or cardiovascular comorbidities

Hypertension in elderly patients needing well-tolerated long-acting combination therapy

Mechanism & Pharmacokinetics ▼

Mechanism: Telmisartan blocks angiotensin II AT1 receptors, reducing vasoconstriction and aldosterone secretion. Amlodipine inhibits calcium influx into vascular smooth muscle, causing vasodilation and lowering peripheral resistance.

Pharmacokinetics: Telmisartan: Peak plasma 0.5–1 h, highly protein-bound, hepatic metabolism, half-life ~24 h. Amlodipine: Peak plasma 6–12 h, extensively protein-bound, hepatic metabolism, half-life ~30–50 h, excreted mainly in urine as metabolites.

Dosage & Administration ▼

Condition	Recommended Dose	Frequency
Essential Hypertension	Telmisartan 40 mg + Amlodipine 5 mg	Once daily; may increase to 80/10 mg if needed
Elderly / hepatic impairment	Telmisartan 20 mg + Amlodipine 2.5–5 mg	Once daily, adjust based on BP response and tolerability

Note: Administer orally with or without food. Monitor blood pressure, kidney and liver function as needed.

Side Effects ▼

Dizziness, headache

Fatigue, nausea

Peripheral edema (common with amlodipine)

Hypotension, syncope

Rare: Angioedema, hepatic enzyme elevation, arrhythmia

Contraindications ▼

Hypersensitivity to telmisartan, amlodipine, or other components

Pregnancy (2nd and 3rd trimester)

Severe hepatic impairment (Telmisartan / Amlodipine)

Severe hypotension or cardiogenic shock

Drug Interaction ▼

Other antihypertensives: additive BP lowering

Potassium-sparing diuretics, ACE inhibitors: risk of hyperkalemia (Telmisartan)

NSAIDs: may reduce antihypertensive effect and increase renal risk

CYP3A4 inhibitors: may increase Amlodipine levels

Pregnancy & Lactation ▼

Telmisartan: Contraindicated in 2nd and 3rd trimester

Amlodipine: Use only if benefit outweighs risk

Excretion in breast milk unknown; avoid or monitor infant

Clinical / Research Summary ▼

Therapeutic Role: Provides dual mechanism for blood pressure control in patients inadequately controlled on monotherapy; improves cardiovascular protection.

Clinical Effectiveness: Reduces systolic and diastolic BP effectively; combination therapy improves adherence and long-term BP control.

Safety Profile: Well tolerated; monitor BP, liver and kidney function, electrolytes; peripheral edema common.

Current Research: Focus on long-term cardiovascular outcomes, prevention of hypertension-related organ damage, and optimal dosing strategies.

Patient Counseling Points ▼

Take at the same time daily, preferably in the morning

Maintain adequate hydration

Report dizziness, fainting, or swelling of ankles/feet

Do not discontinue suddenly

Regularly monitor blood pressure, kidney and liver function

Storage & Handling ▼

Store below 30°C, protect from moisture and light

Keep out of reach of children